The potency of KAN0439834 to induce apoptosis in CLL cells was as strong as that of venetoclax, a BCL-2 inhibitor approved for treating patients with CLL in in vitro assays. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.